.svg){kind=small}
.png)
We’re pleased to share the latest article from our Director of Regulatory Strategy & Pharmacovigilance, Dr Lisa Campbell, in DIA Global Forum. In this piece, Dr Lisa Campbell and co-author William Hind explore how the industry can move from awareness of the female data gap to meaningful, measurable change across the clinical trial lifecycle.
The article highlights that awareness of the problem is no longer the challenge. The focus now is on consistent implementation, embedding inclusion throughout clinical development, generating meaningful evidence, and ensuring progress is supported by measurement and accountability.
👉 Read the full article: From Inclusion to Impact: Closing the Female Data Gap in Clinical Trials
.avif)
